Formulation: A crystalline solid
Formal Name: 3-bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxy-benzamide, monohydrochloride
Purity: ≥98%
Formula Markup: C16H23BrN2O3 • HCl
Formula Weight: 407,7
Shelf life (days): 1460
CAS Number: 73220-03-8
Notes: Remoxipride is an atypical antipsychotic and dopamine D2 receptor antagonist (Ki = 0.2 µM).{58006} It is selective for the dopamine D2 receptor over a panel of 33 receptors, neurotransmitter transporters, and ion channels at 10 µM but does inhibit the sigma (σ) receptor (Ki = 0.065 µM). Remoxipride (2-20 µmol/kg, i.p.) increases striatal 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels in rats.{58007} It inhibits apomorphine-induced stereotypy and hyperactivity in rats with ED50 values of 5.6 and 0.8 µmol/kg, respectively.{58008} Formulations containing remoxipride have previously been used in the treatment of schizophrenia.
English
Deutsch
